Carriers of these CPGs are vulnerable to familial cancers or inherited cancer syndromes, which could overlap with lung cancers, i.e. BRCA2 in hereditary breast/ovarian cancer [51], APC in familial adenomatous polyposis [60] and TP53 in Li-Fraumeni Syndrome [52–59]. Here, BRCA2 is linked to lung carcinoma.